ArticleBiomolecules & biomedicine2025
Letrozole versus coenzyme Q10 plus Clomiphene citrate for women with Polycystic Ovarian Syndrome: An efficacy and safety analysis.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clomiphene citrate is a well-established treatment for Polycystic Ovarian Syndrome (PCOS) but has poor efficacy and adverse effects. Coenzyme Q10 supplementation improves mitochondrial function. Letrozole has been reported to be effective with fewer adverse effects but is not approved for PCOS by the USFDA. This is a retrospective study in women diagnosed with PCOS to assess treatment with either 2.5 mg/day letrozole (LO cohort, n = 103) for 5 days per cycle (for 9 cycles). The QC group received additional doses of 50 mg coenzyme Q10 three times daily (QC cohort, n = 123). A third group received only 100 mg/day clomiphene citrate (CC cohort, n = 155) from the second day of the menstrual cycle for 5 days. After treatment, the duration of the menstrual cycle decreased across all cohorts (P < 0.001 for all), with a smaller reduction observed in the LTZ cohort compared to the QC and CC cohorts (P < 0.05 for all). The number of conceived pregnancies in the LTZ cohort (P < 0.0001) and the CC + QC cohort (P < 0.0001) was significantly higher than in the CC only group. Similarly, conception was higher in the CC + Q10 group than in the CC only group (P < 0.0001 for both groups). Letrozole versus clomiphene citrate plus coenzyme Q10 showed similar efficacy in achieving pregnancy in women with PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.